Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Collagen Cross-Linking for Keratoconus
NCT00841386Phase 3Unknown
- Sponsor
- University at Buffalo
- Start
- Sep 2008
- Primary completion
- Dec 2011
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Ricrolin in keratoconus (2 arms), sponsored by University at Buffalo. Primary endpoints: Best Corrected Visual Acuity at 24 months, Spherical Equivalent Power of the Cornea at 24 months and 2 more. Status: unknown.
02
Drugs
Ricrolin
03
Conditions
keratoconus
Beyond the preview
Go deeper on NCT00841386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841386.